NICE has said Biogen's Tysabri can now be used by the NHS in England and Wales to treat highly active relapsing-remitting ...

Via well-designed AI tools and workflows, trial sponsors are aiming to unify cross-functional data ecosystems to enable a ...

Novo Nordisk has been handed a crucial legal win by China's Supreme Court, which has upheld the company's patent protection ...

As the celebrations for the end of 2025 gathered pace, the FDA delivered a year-end blow to Corcept Therapeutics with a ...

Denmark's Genmab has decided not to continue the development of a drug for cancer, acasunlimab, which had reached phase 3 testing, after a review of its medicines pipeline. The decision to end the ...